LQDA VS SPRY Stock Comparison

Performance

LQDA
100/100

LQDA returned 32.09% in the last 12 months. Based on SPY's performance of -13.52%, its performance is above average giving it a score of 100 of 100.

SPRY
10/100

SPRY returned -30.41% in the last 12 months. Based on SPY's performance of -12.75%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

LQDA
88/100

4 analysts offer 12-month price targets for LQDA. Together, they have an average target of 12, the most optimistic target put LQDA at 17 within 12-months and the most pessimistic has LQDA at 3.

SPRY

"Analyst Price Targets" not found for SPRY

Sentiment

LQDA
68/100

LQDA had a bullish sentiment score of 67.78% across Twitter and StockTwits over the last 12 months. It had an average of 2.48 posts, 3.23 comments, and 3.61 likes per day.

SPRY

"Sentiment" not found for SPRY

Technicals

LQDA
29/100

LQDA receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

SPRY
61/100

SPRY receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.

Earnings

LQDA
10/100

LQDA has missed earnings 11 times in the last 20 quarters.

SPRY
51/100

SPRY has missed earnings 2 times in the last 20 quarters.

Profit

LQDA
10/100

Out of the last 20 quarters, LQDA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

SPRY
10/100

Out of the last 7 quarters, SPRY has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

LQDA
48/100

LQDA has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

SPRY
48/100

SPRY has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Liquidia Corporation Common Stock Summary

Nasdaq / LQDA

Healthcare

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

ARS Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / SPRY

Healthcare

Biotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Power up your portfolio